ClinicalTrials.gg
CompletedNCT07009262ICTOSUpdated Jan 13, 2026

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

An observational study in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
88
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Started
2025
the only one that year
Observational
Only one
of the 12
Registered
10th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2025, is the only observational one, and was the 10th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a self-reported diagnosis of HAE Type I or II who take icatibant to treat HAE attacks

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 12 years of age and older
  2. Diagnosis of HAE Type I or II, based on US Hereditary Angioedema Association (HAEA) database records and/or verbal confirmation from the patient
  3. Currently using icatibant to treat HAE attacks
  4. If a patient is receiving long-term prophylactic treatment, they must have been on a stable dose and regimen for at least 3 months prior to the Screening Visit
  5. Patient has had at least 2 HAE attacks in the 3 months prior to the Screening Visit, as self-reported verbally by the patient
  6. Patient is able to read, understand, and complete the eDiary
  7. Patient is willing and able to adhere to all protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or angioedema associated with urticaria
  2. Use of angiotensin-converting enzyme inhibitors
  3. Participation in any gene therapy treatment or trial for HAE
  4. Participation in any interventional clinical trial within 4 weeks prior to screening
  5. Any pregnant or breastfeeding patient
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
88 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Type I or II Hereditary Angioedema Using Icatibant for On-demand Treatment of Attacks.

    Other: Inapplicable

Interventions

  • OtherInapplicable

    Inapplicable

06

What researchers measure

Primary outcomes

  1. Patient Global Impression of Change (PGI-C)

    time to beginning of symptom relief defined as at least ''a little better'' (2 time points in a row)

    Time frame: Within 12 hours of the first Icatibant dose adminstration

Secondary outcomes

  1. Patient Global Impression of Severity (PGI-S)

    Time to first incidence of decrease from baseline (2 time points in a row)

    Time frame: Within 12 hours of the first Icatibant dose adminstration

  2. PGI-S: Time to Complete HAE Attack Resolution

    time to HAE attack resolution, defined as ''none''

    Time frame: Within 24 hours of the first Icatibant dose adminstration

  3. Return to normal function

    Time to return to normal daily activities. Date/Time or one of the following options: * Not Applicable - daily activities were not affected * not yet returned to normal activities

    Time frame: At 48 hours after first Icatibant dose adminstration

  4. General Anxiety Numeric Rating Scale (GA-NRS): Cumulative GA-NRS

    Patient is asked 'How anxious do you feel right now?' 11-point numeric scale, 0-10 with 0=Not at all anxious and 10=Extremely anxious

    Time frame: over 12 and 24 hours of the first icatibant administration

07

Study locations

1 site
  • KalVista Investigative Site
    Fairfax, Virginia 22030, United States
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing but only after deidentification of individual patient data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Nov 2025, 7 months.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Jun 6, 2025
StartActual
Apr 21, 2025
Primary completionActual
Nov 25, 2025
CompletionActual
Nov 25, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07009262
Collaborators
US Hereditary Angioedema Association
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Apr 21, 2025
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Jan 13, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion